Matherials

Publications

  • Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
    (2021) Leukemia
    ___
  • Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
    (2021) Leukemia
    ___
  • Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice
    (2021) Leukemia
    ___
  • IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
    (2021) Frontiers in Oncology
    ___
  • How I diagnose and treat NPM1-mutated AML
    (2021) Blood
    ___
  • Actinomycin d targets npm1c-primed mitochondria to restore pml-driven senescence in aml therapy
    (2021) Cancer Discovery
    ___
  • NPM1-mutated acute myeloid leukemia: From bench to bedside
    (2020) Blood
    ___
  • Enasidenib and ivosidenib in AML
    (2020) Minerva Medica
    ___
  • GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
    (2019) Leukemia
    ___
  • BRAF V600E mutation in hairy cell leukemia: From bench to bedside
    (2016) Blood
    ___
  • Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia
    (2015) New England Journal of Medicine
    ___
  • Dactinomycin in NPM1-Mutated acute myeloid leukemia
    (2015) New England Journal of Medicine
    ___
  • Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
    (2015) Blood
    ___
  • Mouse models of NPM1-mutated acute myeloid leukemia: Biological and clinical implications
    (2015) Leukemia
    ___
  • Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics
    (2015) British Journal of Haematology
    ___
  • The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model
    (2013) Blood
    ___
  • Mutational landscape of AML with normal cytogenetics: Biological and clinical implications
    (2013) Blood Reviews
    ___
  • CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice
    (2010) Blood

Contact Info

toClinics s.r.l.s.

Via G. Duranti, 67
06100 Perugia, Italy
VAT 03817540549

+39-123-45-67-890

info@toclinics.com
info@pec.toclinics.com

Social Info

We are a service of pharmacological preclinical testing for precision medicine, a shared management with the customers and a unique disease models portfolio.

toClinicsFighting cancer is our mission